Daniel J. George, MD, presented “Relugolix and Concomitant Treatment for Advanced Prostate Cancer” for the Grand Rounds in Urology audience in April 2021.
How to cite: George, Daniel J. “Relugolix and Concomitant Treatment for Advanced Prostate Cancer” April 2021. Accessed Nov 2024. https://dev.grandroundsinurology.com/relugolix-and-concomitant-treatment-for-advanced-prostate-cancer/
Summary:
Daniel J. George, MD, Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine, comments on research presented at the 2021 GU ASCO conference about the recent approval of Relugolix and concomitant therapies. He first notes the results of the HERO trial in which Relugolix was shown to be superior to Leuprolide in continuous suppression of testosterone levels in men with advanced prostate cancer. As a follow up to the study, researchers looked at a subset of patients who received concomitant treatment, either radiation therapy to metastatic or primary disease site or drug therapy with Docetaxel or Enzalutamide. Dr. George highlights that patients on Relugolix and additional drug therapy had continued testosterone suppression equal to those on Relugolix alone and lower testosterone levels than patients on Leuprolide. He adds that there were no safety concerns with regard to toxicity. Notably, the HERO trial found a 54% reduction in serious cardiovascular events between Relugolix and Leuprolide. In summary, the study suggests that Relugolix can be safely combined with other therapies and that additional research is needed.
For more on this topic, visit our Next Generation ADT Learning Center.
ABOUT THE AUTHOR
Dr. Daniel J. George is a Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is Co-leader for the DCI Center for Prostate and Urologic Cancers. He an internationally recognized clinical researcher and thought leader in GU malignancies, with over 150 peer-reviewed publications. His areas of research include new drug development and biomarkers of GU cancers with an emphasis on health disparities. Dr. George is principal investigator of the Duke site for the Department of Defense (DOD) Prostate Cancer Clinical Trials Consortium since 2006, specializing in Phase I and II studies in prostate cancer. He is also the PI of the MaRCC registry in advanced renal cell carcinoma and Co-PI of the PCF 5000, an international, multi-sponsor supported registry in advanced prostate cancer. Nationally, Dr. George has served on the ASCO scientific committee and the Conquer Cancer Foundation grants review committee, and is chair for 2019-20. He alsoserves on two grant committees for AACR. He is the scientific leader for kidney cancer in the Alliance Cooperative Group since 2011 and serves on the Alliance GU scientific committee, NCI GU Steering Committee and the NCI Renal Task Force. He serves as a senior editor for Clinical Cancer Research and Co-editor in Chief of Clinical Advances in Hematology and Oncology.
